Comparative study on the effectiveness of antifungal agents in different regimens against vaginal candidiasis

被引:21
作者
Mikamo, H [1 ]
Kawazoe, K [1 ]
Sato, Y [1 ]
Hayasaki, Y [1 ]
Tamaya, T [1 ]
机构
[1] Gifu Univ, Sch Med, Dept Obstet & Gynecol, Gifu 5008705, Japan
关键词
candidiasis; itraconazole; fluconazole; clotrimazole;
D O I
10.1159/000007136
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: A study was carried out to compare three treatment regimens for vaginal candidiasis. Methods: A total of 150 women with clinical and mycological evidence of vaginal candidiasis were randomized to receive daily a 200-mg dose of oral itraconazole for 3 days (50 women), a single oral 150 mg dose of fluconazole (50 women), or daily 100 mg dose of intravaginal clotrimazole for 6 days (50 women). They were assessed at 5-15 days (short-term assessment) and again at 30-60 days (long-term assessment) after discontinuation of the treatment. Results: At the short-term or long-term assessment, Candida species were completely eradicated from the vagina in 80 or 74% in the 3-day oral itraconazole group, 76 or 70% in the single oral fluconazole group, and 72 or 60% in the intravaginal clotrimazole group, respectively. The rates of clinical effectiveness were 92 or 88% in the 3-day oral itraconatole group, 80 or 76% in the single oral fluconazole group, and 72 or 58% in the intravaginal clotrimazole group, respectively. Treatment-related side effects were not found in any group. Conclusions: Our study suggests that the treatment of vaginal candidiasis with oral itraconazole or oral fluconazole would be effective and that an oral itraconazole or fluconazole therapy might be one choice in the treatment of vaginal candidiasis.
引用
收藏
页码:364 / 368
页数:5
相关论文
共 19 条
[1]   TREATMENT OF VAGINAL CANDIDIASIS WITH KETOCONAZOLE, A NEW, ORALLY ACTIVE, ANTI-MYCOTIC [J].
BISSCHOP, MPJM ;
MERKUS, JMWM ;
SCHEYGROND, H ;
VANCUTSEM, J ;
VANDEKUY, A .
EUROPEAN JOURNAL OF OBSTETRICS GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 1979, 9 (04) :253-259
[2]  
BISSCHOP MPJM, 1985, TGO-TIJDSCHR THER GE, V10, P587
[3]  
Brammer K. W., 1987, Recent trends in the discovery, development and evaluation of antifungal agents., P151
[4]   ITRACONAZOLE (R-51-211) - A CLINICAL REVIEW OF ITS ANTIMYCOTIC ACTIVITY IN DERMATOLOGY, GYNECOLOGY, AND INTERNAL-MEDICINE [J].
CAUWENBERGH, G ;
DEDONCKER, P .
DRUG DEVELOPMENT RESEARCH, 1986, 8 (1-4) :317-323
[5]  
Cauwenbergh G., 1987, Recent trends in the discovery, development and evaluation of antifungal agents., P273
[6]   PHARMACOKINETIC EVALUATION OF UK-49,858, A METABOLICALLY STABLE TRIAZOLE ANTIFUNGAL DRUG, IN ANIMALS AND HUMANS [J].
HUMPHREY, MJ ;
JEVONS, S ;
TARBIT, MH .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1985, 28 (05) :648-653
[7]  
Mikamo H, 1995, Infect Dis Obstet Gynecol, V3, P7, DOI 10.1155/S1064744995000238
[8]  
MILES MR, 1977, JAMA-J AM MED ASSOC, V238, P1836
[9]  
*MULT STUD GROUP, 1988, EUR J CLIN MICR INF, V6, P364
[10]   EPIDEMIOLOGY OF RECURRENT VULVO-VAGINAL CANDIDIASIS - IDENTIFICATION AND STRAIN DIFFERENTIATION OF CANDIDA-ALBICANS [J].
OCONNOR, MI ;
SOBEL, JD .
JOURNAL OF INFECTIOUS DISEASES, 1986, 154 (02) :358-363